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was no longer a significant difference between YCF iron 
bioavailability.
Conclusion Our results suggest that ascorbic acid and 
prebiotics in YCF improve iron bioavailability. Ensuring 
that iron is delivered in a bioavailable form would improve 
the nutritional benefits of YCF in relation to ID/IDA 
amongst young children; therefore, further exploration of 
our findings in vivo is warranted.
Keywords Iron · Bioavailability · Prebiotics · Young 
children · Young Child Formulae · Caco-2
Introduction
Iron is essential for growth and neurodevelopment in 
infants and young children (children between the ages of 
1–3). Humans from birth until 3 years of age undergo rapid 
brain growth and development; iron is required for multi-
ple processes underlying this developmental surge includ-
ing myelination, neurotransmitter function, brain energy 
homoeostasis, and neuronal and synaptogenesis [1]. Inad-
equate iron during this period of childhood is associated 
with impaired cognitive and psychomotor development that 
may not reverse even if children become iron-replete later 
in life [2]. Full-term infants are protected from iron defi-
ciency and iron deficiency anaemia (ID/IDA) for the first 
4–6 months after birth as a result of gestationally derived 
iron stores [3]. Unfortunately, for the rest of the critical 
time period up to 3 years of age, children are at high risk 
for ID/IDA because of rapid overall growth and associated 
increased iron needs and often inadequate intake of bio-
available dietary iron [3, 4].
Infant formula is fortified with iron to prevent defi-
ciency [5], and the evidence suggests that this mandatory 
Abstract 
Purpose Iron is essential for development and growth 
in young children; unfortunately, iron deficiency (ID) is 
a significant public health problem in this population. 
Young Child Formulae (YCF), milk-derived products forti-
fied with iron and ascorbic acid (AA, an enhancer of iron 
absorption) may be good sources of iron to help prevent 
ID. Furthermore, some YCF are supplemented with prebi-
otics, non-digestible carbohydrates suggested to enhance 
iron bioavailability. The aim of our study was to evaluate 
iron bioavailability of YCF relative to prebiotic and AA 
concentrations. We hypothesised that YCF with the highest 
levels of prebiotics and AA would have the most bioavail-
able iron.
Methods We used the in vitro digestion/Caco-2 cell model 
to measure iron bioavailability from 4 commercially avail-
able YCF with approximately equal amounts of iron, but 
varying amounts of: AA and the prebiotics fructo- and 
galacto-oligosaccharides. Caco-2 cell ferritin formation 
was used as a surrogate marker for iron bioavailability.
Results The YCF with the highest concentration of prebiot-
ics and AA had the highest iron bioavailability; conversely, 
the YCF with the lowest concentration of prebiotics and 
AA had the lowest. After the addition of exogenous prebi-
otics, so that all tested YCF had equivalent amounts, there 
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fortification is effective—in the developed world less than 
5% of infants under 12 months have IDA [3, 6]. However, 
the prevalence of ID/IDA increases between 1–3 years of 
age, ranging from 6 to 15% in the developed world [7, 8], 
due to accelerated growth at this developmental stage, and 
also possibly the switch from formula to cow’s milk that 
has less iron compared with formula [9–11]. In response, 
the food industry has developed “Young Child Formulae” 
(YCF), milk-derived products fortified with multiple micro-
nutrients and other dietary factors, aimed at 1- to 3-year-old 
children. YCF contain more iron compared with cow’s milk 
and are also fortified with ascorbic acid, a known enhancer 
of non-haem iron absorption.
There are numerous commercially available YCF 
throughout the developed world. In the United Kingdom 
(UK), according to the Diet and Nutrition Survey of Infants 
and Young children, 18% of children between 12 and 
18 months received YCF as part of their diet, representing 
a significant number of children consuming these products 
[12]. Furthermore, a cross-sectional study of 1- to 2-year-
old children conducted in France found that use of YCF 
was associated with improved dietary iron intake compared 
with children exclusively receiving cow’s milk [10]; how-
ever, the specific nutrient composition of the YCF being 
consumed with reference to modifiers of iron absorption 
was not specified, nor were iron status markers measured 
in study subjects to assess whether the observed increase in 
iron intake correlated with good iron status.
In addition to added iron and ascorbic acid, several 
YCF products are supplemented with prebiotics. Prebiot-
ics are non-digestible dietary substances, typically oligo-
saccharides such as fructo- and galacto-oligosaccharides 
(FOS and GOS, respectively) that encourage the growth 
of beneficial microorganisms in the large intestine [13, 
14]. Prebiotics have also been shown to improve the bio-
availability of minerals, although results with regard to 
iron are not consistent [15]. The type and amount of added 
prebiotic varies between YCF, and some YCF do not have 
any added prebiotics (source of information: manufactur-
ers’ nutrition labels and websites). Of note, The European 
Society for Pediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN) Committee on Nutrition in a recent 
review found that there was no evidence of adverse effects 
from the addition of prebiotics to formula; however, they 
also concluded that evidence was insufficient to recom-
mend routine supplementation and that further research 
was needed [16]. The European Commission regulates 
infant and follow-on formulae composition in the European 
Union and stipulates a maximum amount of prebiotics that 
may be added, but does not make more specific reference to 
recommended amounts (Commission Directive 2006/141/
EC, reviewed and updated July 2016) [17].
Although young children are at increased risk for ID/
IDA, there is also concern that excess dietary iron may 
affect their gut microbiome with negative local and sys-
temic health effects [18]. A study conducted in Kenya 
found that intake of iron-fortified foods led to a higher 
number of gut pathogens, increased intestinal inflamma-
tion and more frequent diarrhoea episodes requiring treat-
ment [19]. In another study, consumption of iron-fortified 
biscuits was associated with an unfavourably altered gut 
microbiome [20]. Unabsorbed iron reaching the colon 
is suggested to mediate these effects [21]. Of note, how-
ever, a study in children from 9 to 18 months living in the 
UK, who continued to receive iron supplemented formula, 
found no evidence of adverse effects over the 9 months of 
the study even in iron-replete children [22]; thus, the effects 
of iron on the young gut may vary depending on underlying 
risk for gut inflammation and infection. Nonetheless, foods 
fortified with highly bioavailable iron are desirable because 
of their efficacy in improving iron nutriture as a result of 
increased absorption. They may also, as a consequence 
of improved small bowel uptake, deliver less iron to the 
large intestine that may have long-term health implications 
related to the gut microbiome.
The objective of this study was to compare the iron bio-
availability of four YCF commonly consumed in the UK 
containing approximately equal amounts of iron, but with 
different ascorbic acid concentrations, and varying amounts 
and types of FOS and GOS. The aim of our research was to 
evaluate YCF iron bioavailability relative to supplemental 
prebiotic and ascorbic acid concentrations. We utilised the 
Caco-2 cell/in vitro digestion model with the formation of 
Caco-2 cell ferritin as a surrogate marker for cellular iron 
uptake. This model has been used in multiple studies to 
assess iron bioavailability from foodstuffs including milks, 
milk-derived products and infant formulae, for examples 
see [23–25]. We hypothesised that the YCF with the highest 
concentrations of prebiotics and ascorbic acid would have 
the highest levels of bioavailable iron, while the YCF with 
no added prebiotics and lower levels of ascorbic acid would 
have the lowest iron availability.
Materials and methods
Reagents
All chemicals and enzymes, unless otherwise stated, were 
purchased from Sigma-Aldrich (UK). Acids required for 
glassware cleaning and in vitro digestions were acquired 
from VWR (UK). Thermo Fisher Scientific was the pro-
vider of cell culture media, flasks, tissue culture plates 
and cell culture reagents. Twenty-four hours prior to each 
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experiment glass- and plastic-ware needed for experi-
ments were soaked in 10% (v/v) trace metal grade 68% 
nitric acid and then subsequently rinsed with 18 mΩ pure 
water.
GOS powders (100% purity) used in experiments were 
either purchased from Megazyme International (Ireland), 
or kindly provided by King-Prebiotics. FOS powder (100% 
purity) was purchased from Health Plus (Seaford, East 
Sussex).
Samples
Four YCF were obtained from three different leading UK 
supermarkets on three separate occasions, herein identi-
fied as YCF A, B, C and D. Products were tested before 
the use by date and within 1 month of purchase. YCF were 
stored unopened at room temperature, similar to their dis-
tribution and market environment. YCF A and B were forti-
fied with equivalent amounts of prebiotics in the forms of 
GOS and FOS by the manufacturer; YCF A specified the 
ratio of GOS to FOS, but neither YCF A nor B provided 
nutrient label information on the specific forms of GOS 
and FOS used. YCF C was fortified with GOS alone by 
the manufacturer, and at a lower concentration compared 
with YCF A and B, and YCF D had no added prebiotics. 
YCF A, B and D had 1.2 mg iron/100 ml product; YCF 
C had 1.1 mg/100 ml. Ascorbic acid levels also differed 
between YCF; YCF A and B had the highest reported lev-
els, followed by YCF D. YCF C had the lowest reported 
concentration of vitamin C. The nutrient composition of 
the various YCF in relation to total iron, ascorbic acid and 
prebiotics is provided below (Table 1). 
Cell culture
The TC7 Caco-2 cell line was used for all experiments 
(kindly endowed to the Sharp laboratory by Monique 
Rousset and Edith Brot-Laroche, INSERM U505, [26]); 
work with this cell line investigating iron uptake and bio-
availability has been published in numerous studies, for 
example [27–29].
Details of the in vitro digestion method have been pre-
viously published [27, 28, 30]. Briefly, cells were grown 
in T75 flasks and seeded into six-well tissue culture plates 
for experiments. According to the method developed by the 
Glahn laboratory [30], the in vitro digestions were carried 
out 13–15 days post-seeding. The media used to feed cells 
was Dulbecco’s Modified Eagle Medium supplemented 
with 10% v/v foetal bovine serum, 1% penicillin–strepto-
mycin, 4 mmol/L L-glutamine, 1% non-essential amino 
acids.
Media were changed to supplemented MEM (10 mmol/L 
PIPES [piperazine-N, N′-bis (2-ethanesulfonic acid)], 1% 
antibiotic/antimycotic solution, 11 µmol/L hydrocorti-
sone, 0.87 µmol/L insulin, 0.02 µmol/L sodium selenite 
(Na2SeO3), 0.05 µmol/L triiodothyronine and 20 µg/L 
epidermal growth factor), without foetal bovine serum, to 
ensure satisfactory cell growth but with low basal media 
iron levels [30, 31].
YCF and in vitro digestions
All experiments were carried out with freshly prepared 
reagents and freshly opened cartons of YCF; only liquid 
forms of YCF were tested in experiments. 1.8–2 ml of YCF 
sample was used per digestate depending on sample iron 
concentration. 
All experiments contained a set of controls: a digest with 
no added iron to ensure no iron contamination of our sys-
tem (Blank food digest); a reference digest of 30 µmol/L 
Fe (Fe alone) equivalent to the iron concentration in YCF 
digestates; and a positive control digest of 30 µmol/L Fe 
and 300 µmol/L ascorbic acid (Fe + AA at a 1:10 molar 
ratio).
The digests were prepared as previously described [8]. 
Briefly, pepsin was added to the controls or YCF samples 
to initiate the gastric phase of the in vitro digestion (tested 
controls or samples herein referred to as digestates), and 
the pH adjusted to pH 2. As the literature suggests the 
stomach pH of infants and young children may be higher 
compared with adults [32], we also conducted a subset 
of experiments, with a limited number of YCF, in which 
Table 1  Nutrient composition 
of YCFs A–D according to 
the manufacturers’ labels and 
websites
Nutrient (mg/100 ml unless otherwise noted) YCF sample
A B C D
Ascorbic acid 15 15 10 12
Iron 1.2
(FeSO4)
1.2
(Fe2 lactate)
1.1
(FeSO4)
1.2
(FeSO4)
FOS 120 Not stated 0 0
GOS 1080 Not stated 500 0
Total FOS and GOS 1200 1200 N/a 0
Fibre (g/100 ml) 0.8 0.8 0.5 0
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digestions were initiated with a gastric phase pH of 4. Dur-
ing the gastric phase (at both pHs), digestates were placed 
in a shaking incubator for 75 min. Subsequently, the pH 
was raised to 5.0–6.0, bile salts and pancreatin digestive 
enzymes were added, and the pH was readjusted to 6.9–7.0 
followed by another 75 min in the shaking incubator to 
mimic the small intestinal phase of digestion.
A chamber was created over each individual cell cul-
ture well containing the Caco-2 cell monolayer using a 15 
kD molecular weight cut-off dialysis membrane fitted over 
a Transwell insert and held in place with a silicon ring. 
1.5 mL of the digestate was then placed in the chamber that 
was in contact with the cell culture media of the well. The 
tissue culture plates were placed in a 37 °C incubator for 
60 min, while in the incubator they were rotated using a 
platform-fitted multi-function 3D rotator set at 6 oscilla-
tions/min. The inserts were then removed and an additional 
1 mL of supplemented MEM added to each well. The cells 
were returned to the incubator for the following 22 h and 
then harvested for ferritin.
All YCF samples were tested on a minimum 
of three separate occasions at gastric phase pH 2, 
with n = 6 for each treatment. Further in vitro digestions 
were carried out on one or more occasions with n ≥ 6 
(specified on figures and tables) for: gastric phase diges-
tion at pH 4; YCF with exogenously added GOS and FOS 
so that total levels of prebiotics were equivalent across all 
YCF samples; YCF with exogenously added ascorbic acid 
so that levels of ascorbic acid were equivalent across all 
YCF samples; YCF with exogenously added GOS, FOS 
and ascorbic acid so that levels were equivalent across all 
YCF; and heat-treated digestates.
Cell harvest and ferritin analysis
Cells were harvested as previously described [27, 28]. In 
brief, the monolayers of cells were rinsed and then detached 
with cell lysis buffer (CelLyticTM—Sigma-Aldrich) and 
subsequently centrifuged at 6000×g for 6 min; superna-
tant was separated and stored at −80 °C. The samples were 
analysed for ferritin using the SpectroFerritin MT Enzyme 
Linked Immunoassay (ELISA; RAMCO, TX, USA). Fer-
ritin levels were adjusted for varying cell numbers/well 
by measurement of cell protein/well (Pierce Protein BCA 
assay) and expressed as ng ferritin/mg of cell protein.
Ascorbic acid analysis
All samples, and GOS and FOS used to fortify Samples 
C and D to levels equivalent with Samples A and B, were 
analysed for reduced ascorbic acid (herein referred to 
rAA) concentrations using the 2,6-Dichloroindophenol 
Titrimetric method (AOAC 985.33). Briefly, 5 ml of the 
YCF being analysed, or 5 g of the GOS and FOS pow-
ders being tested (prebiotic powders were initially ground 
in a mortar and pestle with fine sand, then strained), were 
added to a mixture of glacial acetic acid and metaphos-
phoric acid, and titrated with a freshly prepared indophe-
nol standard solution. A rAA standard solution was freshly 
prepared and used to standardise the indophenol titration 
solution. rAA levels were calculated based on the ascorbic 
acid equivalent mass titrated to 1 ml of indophenol indi-
cator solution (in relation to the rAA standard solution), 
adjusted for dilutions factors and the test solution blank 
titration level.
Heat treatment
To evaluate the contribution of ascorbic acid to iron uptake, 
selected YCF digestates, and the iron plus ascorbic acid 
positive control, were treated for 7.5 min in a 100 °C water 
bath and then plunged into ice, in order to degrade the 
ascorbic acid [33].
Statistical analysis
Statistical analysis of the data was performed using Graph-
Pad Prism (version 6.0c GraphPad Software, San Diego, 
CA, USA). In vitro digestion experiments were analysed 
using the statistical methods of Motulsky [34]. Data are 
presented as mean ± SEM and were analysed by one-way 
ANOVA followed by either Tukey’s multiple comparisons 
test (all-pairwise across experimental groups) or, where 
the comparison being made was only between select pairs, 
Sidak’s multiple comparisons test. Differences between 
means were considered significant at p ≤ 0.05. Ordered 
increases in data were tested using the nonparametric Jon-
ckheere–Terpstra test. Ordered increases were considered 
significant at p ≤ 0.05. The Jonckheere–Terpstra test was 
computed in Microsoft Excel. Unless stated otherwise, 
in the results section the word “significantly” is used to 
denote statistical significance as indicated by the relevant p 
shown in parenthesis at the end of the statement.
Results
Iron bioavailability of Tested YCF at gastric phase pH 2
Data on iron bioavailability of YCF A–D from the in vitro 
digestion/Caco-2 cell model are presented in Fig. 1.
YCF A and B, which had the highest levels of prebiot-
ics and ascorbic acid, had the highest iron bioavailability 
as measured by ferritin formation. YCF A ferritin levels 
were 43, and 62% greater than YCF C and D, respectively 
(p < 0.0001). YCF B ferritin levels were 25%, greater 
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than YCF C, although this was not statistically significant 
(p = 0.1007), and 41% greater than YCF D (p = 0.0113). 
YCF C and D did not have statistically different ferritin 
concentrations.
Iron bioavailability of tested YCF at gastric pH 4
YCF A, B and D (representing the YCF with the highest 
and lowest bioavailability, respectively) were tested using 
a gastric phase pH of 4 (Table 2). Changing the pH to 4 did 
not alter iron bioavailability for any of the tested YCF.
Iron bioavailability of YCF to which exogenous GOS 
and FOS were added
Data on iron bioavailability for these experiments are pre-
sented in Fig. 1.
Ferritin levels in YCF C and D were significantly 
lower than those in YCF A. Ferritin levels of YCF C were 
10.25 ng ferritin/mg protein lower than YCF A (30% 
lower; p < 0.0001), and ferritin levels of YCF D were 
13.01 ng ferritin/mg protein lower than YCF A (38% lower; 
p < 0.0001). While not statistically significant, ferritin lev-
els of YCF C were also 20% lower than YCF B ferritin lev-
els (p = 0.1007). YCF D was significantly lower than YCF 
B by 29% (p = 0.0113). YCF C originally contained 0.5\,g 
GOS/100 ml milk, whereas YCF D originally contained no 
supplemental prebiotics. After the addition of a mixture of 
GOS and FOS to both YCF C and D, so that total prebiotic 
levels were equivalent to those found in YCF A and B, there 
Bla
nk
GO
S&
FO
S A
lon
e
Fe
 al
on
e 
YC
F A
YC
F B
YC
F C
YC
F D
YC
F C
 + 
GO
S&
FO
S
YC
F D
 + 
GO
S&
FO
S
Fe
+A
A
0
10
20
30
40
50
ng
 fe
rri
tin
 / 
m
g 
pr
ot
ei
n
a
bd
bc
bd
bc
e
a
c
d
bc
Fig. 1  Caco-2 ferritin levels from treatment of cells with digestates 
of controls, YCF A–D, and YCF C and D supplemented with GOS 
and FOS to levels equivalent to those found in YCF A and B. Values 
presented are means of data normalised to the Fe reference control 
(Fe alone) ± SEM (n ≥ 18 for YCF alone, all others n ≥ 6). Treat-
ment with YCF A yielded the highest ferritin compared with all other 
YCF although not statistical when compared to YCF B. The addition 
of GOS and FOS to YCF C and D increased ferritin to levels statisti-
cally equivalent to YCF A and B. Based on an ANOVA (p < 0.0001) 
with Tukey’s multiple comparisons test, post hoc analysis done on an 
all-pairwise basis; means with different superscript letters in a col-
umn are statistically different (p ≤ 0.05)
Table 2  Ferritin values of Caco-2 cells treated with YCF A, B and D 
at gastric phase digestions of pH 2 compared with pH4
Values presented are the mean ± SEM. There was no statistical dif-
ference between pH2 and pH4 gastric phase digestions for any of the 
three samples using Sidak’s multiple comparisons test (n ≥ 6)
YCF sample pH2
ng ferritin/mg protein
pH4
ng ferritin/mg protein
p value
YCF A 34.1 ± 0.9 29.9 ± 1.1 0.4239
YCF B 29.7 ± 1.4 30.1 ± 2.5 0.9990
YCF D 21.1 ± 2.8 17.1 ± 3.2 0.5407
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Fig. 2  a Ferritin levels of Caco-2 cells exposed to control digests, 
both with, and without, heat treatment to degrade ascorbic acid (AA). 
Heat treatment of the positive control (Fe + AA at a 1:10 Fe/AA 
molar ratio) decreased the enhancing effect of AA on iron uptake; 
ferritin formation was equivalent between the Fe alone and Fe + AA 
controls. Based on an ANOVA (p = 0.0003) with Tukey’s multiple 
comparison test, post hoc analysis done on an all-pairwise basis; 
means with different superscript letters in a column are statistically 
different (p ≤ 0.0015). b Caco-2 ferritin levels of cells treated with 
YCF A digestates, with, and without, heat treatment, and YCF C 
digestates, with, and without, added AA (≈1:4 Fe/AA molar ratio). 
Ferritin levels of YCF A decreased after heat treatment; ferritin levels 
of YCF C increased after the addition of AA to levels equivalent with 
YCF A; however, ferritin was still less than non-heat-treated YCF A 
levels. All presented values are means normalised to the Fe reference 
control (Fe alone) ± SEM. Based on an ANOVA (p < 0.0001) with 
Tukey’s multiple comparisons test, post hoc analysis done on an all-
pairwise basis; means with different superscript letters in a column 
are statistically different (p ≤ 0.0074)
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was no longer a statistically significant difference between 
the ferritin levels in any of the four tested YCF although 
YCF C and D ferritin levels were still 7.42 and 6.15 ng fer-
ritin/mg protein lower (by 22 and 18%), respectively, com-
pared with YCF A.
Iron bioavailability of YCF relative to ascorbic acid 
with and without heat treatment
YCF A and B had equal amounts of ascorbic acid according 
to stated information on the manufacturer’s label (15 mg 
ascorbic acid/100 ml milk); measured levels were 14.2 
and 16.3 mg rAA/100 ml milk, respectively. Ascorbic acid 
levels in YCF C were reported as 10 mg/100 ml milk (the 
lowest of all tested YCF) and measured as 10.2 mg/100 ml; 
YCF D rAA levels were reported as 12 mg/100 ml and 
measured as 10.1 mg/100 ml.
The reported ascorbic acid/iron molar ratios were 4:1 
for YCF A and B and 3:1 for YCF C and D, respectively. 
Ascorbic acid/iron molar ratios based on measured rAA 
were: 3.75:1; 4.3:1; 3:1; and 2.7:1; for YCF A, B, C and D, 
respectively.
In order to ensure that our heat treatment inactivated the 
ascorbic acid present in YCF samples, we tested whether 
heat-treating our positive control (Fe + AA) affected fer-
ritin formation. Heat treatment of the positive control 
significantly decreased ferritin levels compared with the 
non-heat-treated positive control (p = 0.0002); levels 
were equivalent to those seen in our iron alone controls 
(i.e. iron added to digestates without any added ascorbic 
acid; p = 0.2227) (Fig. 2a). Heat treatment of YCF A sig-
nificantly decreased ferritin levels by approximately 24% 
(from 53.42 to 40.83 ng ferritin/mg protein; p = 0.0074); 
however, YCF A ferritin concentration, even after heat 
treatment, was still significantly higher by 13.52 ng ferritin/
mg protein compared with YCF C levels (the sample with 
the lowest reported and measured AA levels; p = 0.0082). 
Lastly, we added exogenous ascorbic acid to YCF C to 
levels equivalent to those found in YCF A; ferritin lev-
els increased by 5.90 ng ferritin/mg protein, or approxi-
mately 22%, but were still 20.20 ng ferritin/mg protein less 
(38%) than those measured in cells treated with YCF A 
(p = 0.0002; Fig. 2b).
Iron bioavailability of YCF C and D with the addition 
of exogenous GOS and FOS, with, or without, added 
ascorbic acid 
In order to test whether prebiotics and ascor-
bic acid had an additive effect on iron bioavailabil-
ity, we measured ferritin levels of digestates of YCF 
C and D with added GOS and FOS alone, compared 
with digestates of YCF C and D with added GOS 
and FOS and ascorbic acid. There was an ordered 
increase in ferritin formation in the order of digestates of 
YCF C alone, YCF C and GOS and FOS, and YCF C, GOS 
and FOS and ascorbic acid (p = 0.0048; Fig. 3a); simi-
larly, there was an ordered increase in ferritin formation in 
the order of digestates of YCF D alone, YCF D and GOS 
and FOS, and YCF D, GOS and FOS and ascorbic acid 
(p = 0.0001; Fig. 3b).
Discussion
YCF A and B, with the highest levels of prebiotics and 
ascorbic acid, had the highest iron bioavailability as meas-
ured by Caco-2 cell ferritin formation. YCF A ferritin levels 
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Fig. 3  a Ferritin levels of Caco-2 cells treated with digests of: YCF C 
alone; YCF C + GOS and FOS; and YCF C, GOS and FOS, +ascor-
bic acid (AA, 114 µmol/L; ≈1:4 Fe/AA molar ratio). Increase in 
ferritin formation was tested using the Jonckheere–Terpstra test and 
is significant in the order YCF C alone, YCF C + GOS and FOS, 
and YCF C, GOS and FOS, +AA (p = 0.0048). Ferritin levels of 
Caco-2 cells treated with digests of: YCF D alone; YCF D + GOS 
and FOS; and YCF D, GOS and FOS, + AA (114 µmol/L; ≈1:4 
Fe/AA molar ratio). Increase in ferritin formation was tested using 
the Jonckheere–Terpstra test and is significant in the order YCF D 
alone, YCF D + GOS and FOS, and YCF D, GOS and FOS, and AA 
(p = 0.0001)
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were approximately 1.5 times greater than those of YCF C 
and D, while YCF B ferritin levels were approximately 1.3 
times greater than those of YCF C and D. The addition of 
prebiotics (a mixture of GOS and FOS) and ascorbic acid to 
YCF C and D increased iron uptake by approximately 1.5 
and 2.3 times, respectively, but neither exogenously added 
ascorbic acid alone, nor prebiotics alone, elevated ferritin 
levels to those seen in YCF A, suggesting both factors con-
tributed to the greater iron bioavailability of YCF A.
Previous reports in the literature found that an ascorbic 
acid to iron molar ration of 4:1 is associated with higher 
iron bioavailability in high-phytate food products [35]; 
consistent with this in our study YCF A and B, which had 
the most bioavailable iron, also had both higher absolute 
amounts of ascorbic acid and higher ascorbic acid to iron 
molar ratios compared with the other tested YCF.
Relative to prebiotics, the results of our study are con-
sistent with numerous studies, demonstrating prebiot-
ics enhances iron absorption in rodents and pigs [36–40]. 
Potential mechanisms driving this increase included: 
enhanced solubility of iron [40]; a decrease in colonic 
pH [41, 42]; changes in the profile of the gut microbiota 
[43]; a direct effect on iron transporter expression in either 
duodenum or colon [36, 44, 45]; or a systemic decrease in 
inflammation leading to decreased production of hepcidin, 
a peptide secreted by the liver in response to inflammation 
that decreases iron absorption [41]. However, it is not clear 
whether any of these mechanisms would be relevant in our 
short-term in vitro studies.
Results from studies evaluating the effects of prebiot-
ics on iron availability carried out in human beings, and 
also in vitro with the Caco-2 cell line, have been mixed. 
A recent study in women with low iron status who were 
given approximately 20 g/d of the FOS-inulin found that 
although inulin did modify the large bowel microbiome and 
also lowered colonic pH, there was no influence on iron 
absorption as measured by the stable isotope technique; 
iron absorption in the inulin group was 14% higher, but 
this was not statistically significant [46]. Another study car-
ried out in young men using the same method to assess iron 
absorption also found no statistically significant effect of 
inulin, FOS, or GOS on iron absorption, though absorption 
was some 20% higher in the FOS group compared with 
control [47]. Both of these studies were relatively small 
(n = 32, n = 15, respectively) and therefore may have been 
underpowered to detect small, but physiologically relevant, 
increases in iron uptake. Absorption of iron is primar-
ily determined by host iron status, and differences in iron 
absorption from foods containing less potent enhancers 
of absorption (e.g. prebiotics) may not be revealed unless 
some degree of iron deficiency is present, or absolute 
amounts of bioavailable dietary iron are too low to meet 
needs. Our results are consistent with a study carried out 
in infants and young children that demonstrated improved 
iron status amongst children receiving a mixture of prebi-
otic oligosaccharides (type not specified) and probiotics 
[48]. A possible reason for these different study results is 
that inulin may not be the optimal FOS for increasing iron 
absorption. Shorter-chain FOS more closely resemble fruc-
tose [49], which we have shown increases non-haem iron 
bioavailability in the Caco-2 cell model [27]. Our previ-
ous work demonstrated that fructose added to a ferric iron 
solution increased levels of ferrous iron by approximately 
300% [27], suggesting that the observed increase in iron 
bioavailability was caused by fructose reducing ferric iron 
to the more bioavailable ferrous iron. Shorter-chain FOS 
may be better at improving iron bioavailability compared 
with longer-chain FOS-inulin if they share some degree of 
this reducing effect, or secondary to other structural-related 
differences. In support of this, recent work using GOS sug-
gests that specific structural differences in prebiotics alter 
their influence on iron absorption [50]. Lastly, human stud-
ies evaluating the effects of GOS and FOS given together 
on iron bioavailability have not, to the authors’ knowl-
edge, been conducted; the two prebiotics together may act 
synergistically.
Several in vitro studies evaluating the effect of prebiot-
ics on iron uptake have been carried out in the past decade. 
Two Caco-2 cell-based studies evaluating iron bioavailabil-
ity from milk- or soy-based yogurts, and common beans, 
both found that inulin did not improve iron bioavailability 
from the test food matrix [25, 42]. In contrast, and in agree-
ment with our findings, another in vitro study using iron-
fortified cereal biscuits, to which inulin had been added, 
demonstrated improved iron bioavailability that correlated 
with increased iron solubility [51]. Both the yogurt and 
bean-based studies used a higher dose of inulin compared 
with our study (approximately 17 mg vs. 2.4 mg per diges-
tate) and did not add any GOS; the amount of prebiotics 
applied to Caco-2 cells in the biscuit study was not speci-
fied. In conclusion, the positive results in our present study 
may relate to several factors: different dose of FOS; differ-
ent forms of FOS and GOS; and the addition of GOS and 
FOS together to the tested food matrix.
Young children have the highest risk of ID/IDA amongst 
pre-adolescent children. The ESPGHAN Committee on 
Nutrition recommends young children receive a diet rich 
with iron-containing foods and that excess intake of iron-
poor cow’s milk be avoided [3]. However, ID/IDA persists 
in young children, and thus YCF fortified with iron may be 
beneficial, as part of a varied diet, in the prevention of ID/
IDA. In addition, fortified milk products with the most bio-
available iron would also be predicted to deliver less unab-
sorbed iron to the young colon. The findings of this study 
suggest that both prebiotics and ascorbic acid contribute to 
improved iron bioavailability in YCF. However, ascorbic 
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acid is a relatively unstable micronutrient, and levels may 
fluctuate depending on storage conditions and timing of use 
from purchase date [33], whereas prebiotics are relatively 
stable in foods [52, 53]. Thus, the use of both dietary fac-
tors to improve iron bioavailability in fortified milks may 
be complementary.
Several observational studies in Europe [10, 54] found 
that intake of YCF was associated with increased dietary 
intake of iron in young children. A recent cross-sectional 
study carried out in Western Europe amongst healthy 
young children found that 11.9 and 3.9% of tested children 
had ID, and IDA, respectively, and use of cow’s milk as the 
main milk source was associated with an increased risk of 
ID [55]. The prevalence of ID in children primarily receiv-
ing cow’s milk was 19.7% in contrast with children whose 
main source of milk was YCF (ID prevalence 5.4%); this 
difference was highly significant (p < 0.001) [55]. The spe-
cific YCF used in this study were not specified, nor were 
study participants’ intakes of ascorbic acid or prebiotics. 
There are several limitations to our study. Although the 
Caco-2 cell system is a validated model for assessing iron 
bioavailability including in the food matrixes we tested, 
the magnitude of effects may not always be accurate [56]. 
It thus remains for our results to be confirmed in vivo. In 
addition, we did not analyse the specific forms of GOS and 
FOS used in this study, and there is evidence that there is 
structural specificity in terms of the effects of prebiotics on 
iron bioavailability. Studies looking at specific prebiotic 
structure and its relation to iron availability would be help-
ful. Furthermore, although the European Commission regu-
lates the absolute amounts both of prebiotics (and the ratio 
of GOS to FOS) that may be added to YCF, dose–response 
analysis of prebiotic effects on iron bioavailability would 
enable producers to optimise formulation.
In conclusion, use of YCF may contribute significantly 
to iron intake in young children and thus potentially reduce 
ID/IDA; however, in the case of iron, the absolute amount 
ingested does not necessarily reflect the fraction absorbed. 
Therefore, ensuring that iron in YCF is delivered in a bioa-
vailable form, while minimising the delivery of excess iron 
to the young gut, would improve the nutritional benefits of 
YCF. Our results suggest that ascorbic acid and prebiotics 
in YCF improve iron bioavailability. Further in vivo work 
to confirm our results and also to explore whether absolute 
amounts of iron fortification in YCF could be decreased 
through optimisation of concentration and forms of prebi-
otics and ascorbic acid warrants investigation.
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